Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Hospira, Inc.    HSP

No quotes available
-- USD   0.00%
2015 ARRAY BIOPHARMA : cfo steps down, replacement named. (BRIEF)
2015 HOSPIRA : A $90 million payday for Hospira CEO after sale to Pfizer
2015 PFIZER : completes acquisition of injectable drugmaker Hospira
SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensus 
News SummaryMost relevantAll newsSector news 

Hospira : Applauds Delaware Governor’s Signing of Biosimilars Legislation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/30/2014 | 06:42pm CEST

LAKE FOREST, Ill., May 30, 2014 - Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today commended Delaware Gov. Jack Markell for his decision to sign Senate Substitute 1 for Senate Bill 118. This law creates a pathway for the substitution of interchangeable biologic drugs and helps pave the way for patient access to cost savings from biosimilar products.

When biosimilars become available in the United States in the coming years, clinicians will have opportunities to provide their patients with greater accessibility to effective and more affordable biologic drugs. The introduction of biosimilars could help the United States save up to $250 billion over 10 years, according to one report.

"The introduction of biosimilars promises to help put new cost-savings in the hands of patients and states, such as Delaware, that are taking early action to establish clear and transparent policies for the substitution of these high-quality and more affordable biologic products," said Paul Audhya, M.D., vice president, Medical Affairs, Hospira.

The governor's signature on Senate Substitute 1 for Senate Bill 118 allows pharmacists to substitute biosimilars for prescribed biological reference products unless the prescribing physician expressly requests the reference biologic.

Hospira is a market leader in biosimilars in Europe, and expects to submit its first biosimilar to the U.S. Food and Drug Administration (FDA) later this year or in early 2015.


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HOSPIRA, INC.
2015 ARRAY BIOPHARMA : cfo steps down, replacement named. (BRIEF)
2015 HOSPIRA : A $90 million payday for Hospira CEO after sale to Pfizer
2015 PFIZER : completes acquisition of injectable drugmaker Hospira
2015 HOSPIRA : Termination of a Material Definitive Agreement, Completion of Acquisit..
2015 HOSPIRA : and Cerner Expand Agreement to Advance Integration of I.V.-EMR Technol..
2015 PFIZER : Receives Clearance from U.S. Federal Trade Commission for Hospira Acqui..
2015 HOSPIRA : Announces First Installation of Plum 360 Infusion System With Hospira ..
2015 S&P 500 Plans to Add Activision Blizzard, United Continental Holdings
2015 BRIEF : United Airlines to enter S&P 500, replacing Hospira
2015 PFIZER : Gets Clearance from U.S. FTC for Hospira Acquisition
More news
Sector news : Generic Pharmaceuticals
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
04/19 New Management At ICU Medical Has Produced Positive Results
03/21 PFIZER : 30%+ Discount With 4% Yield
2015 PREMARKET BIOTECH DIGEST : Trouble For Anticoagulants, Gilead U.S. Hep C Sales
2015 Hospira Acquisition To Add Shareholder Value For Pfizer
2015 Activision Blizzard, United Continental set to join S&P 500
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
F. Michael Ball Chief Executive Officer & Director
John C. Staley Non-Executive Chairman
Matthew R. Stober Senior Vice President-Operations
Thomas E. Werner Chief Financial Officer & Senior Vice President
Sumant Ramachandra Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HOSPIRA, INC.0.00%0
SUN PHARMACEUTICAL IND..-3.31%28 176
OTSUKA HOLDINGS CO LTD15.96%26 399
ONO PHARMACEUTICAL CO...-8.03%22 039
BIOMARIN PHARMACEUTICA..-10.67%15 190
ASPEN PHARMACARE HOLDI..23.55%11 984
More Results